US Stock Alert: Illumina Plunges on November 12 Due to Disappointing Earnings, Stakeholder Sell-off, and Sector Pullback

Illumina November 12 Interpretation of Sharp Decline

Keywords: performance below expectations, related party reduction, sector pullback

1. After the market close on October 29, 2026, Illumina announced its third quarter results for the fiscal year 2026 ending September 27. Revenue was $1.129 billion, below institutional expectations of $1.154 billion. Product revenue was $946 million, below the expected $974.75 million. Sequencing instrument revenue decreased by 4.7% year-on-year, and microarray instrument revenue dropped 25% year-on-year.

2. On November 3, 2026, SEC documents disclosed that related party Corvex Management LP intends to sell 369,500 shares of common stock, with a total market value of approximately $87.1985 million. Since August 4, 2026, they have cumulatively reduced holdings by 2.0907 million shares.

3. On November 2, 2026, multiple stocks in the gene sequencing sector experienced sharp pullbacks: 10x Genomics dropped 12%, Twist dropped 15%, PacBio dropped 10%. Sector-wide selling pressure dragged down Illumina.

4. Illumina has fallen 27.50% cumulatively in the past five days, facing pressure from an overbought pullback after a significant 52-week gain.

(Disclaimer: This content is summarized and generated by AI technology from publicly available information for reference only and does not constitute investment advice.)